<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97259">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656057</url>
  </required_header>
  <id_info>
    <org_study_id>GALINKUR</org_study_id>
    <nct_id>NCT01656057</nct_id>
  </id_info>
  <brief_title>The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion</brief_title>
  <official_title>The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Filip Krag Knop</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The last couple of years it has been shown that bile acids not only acts as simple
      emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an
      influence on fat digestion and lipid metabolism, but also modulates the energi expenditure
      in (brown) adipose tissue and muscle tissue. This action is due to stimulation of the
      receptor TGR5 by bile acids. Recently scientists have discovered that this receptor in
      rodents is also expressed on the surface of intestinal L-cells (which normally secrets GLP-1
      in respons to nutrient stimulation). The stimulation of this receptor has shown a GLP-1
      secretion from the intestinal cells which is interesting since GLP-1 has a central role in
      the maintainance of a normal glucose tolerance and thus blood sugar. Given the above, bile
      acids has an important impact on intestinal GLP-1 secretion. Whether these scientific
      findings can be proven in human beings is uncertain.

      The primary hypothesis is that stimulating gall bladder emptying via CCK in healthy subjects
      will result in a significant GLP-1 response. We also hypothesize that adding orally
      Metformin or a sequestrant (&quot;a bile acid binder&quot;) will further enhance this GLP-1 response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>GLP-1 response as incremental area under curve (iAUC)</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>c-peptide</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>glucagon</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>GLP-2</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>PYY</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Oxyntomodulin</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>GIP</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Bile acids</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Gastrin</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>CCK</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Gall bladder emptying assessed ultrasonically</measure>
    <time_frame>0, 30, 60, 90</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>-10, 50, 170</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Estimation of satiety via visual analogue scale</measure>
    <time_frame>0, 30, 60, 90, 120, 150, 180</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>Day 1: 1 ml isotone sodium cloride IV infusion Day 2: 24 pmol human CCK/kg/hour IV infusion Day 3: 1 ml isotone sodium cloride IV infusion + orally 3,75 grams of colesevelam Day 4: 24 pmol human CCK/kg/hour IV infusion + orally 3,75 grams of colesevelam Day 5: 1 ml isotone sodium cloride IV infusion + orally 1,5 grams of metformin Day 6: 24 pmol human CCK/kg/hour IV infusion + orally 1,5 grams of metformin</description>
    <other_name>Metformin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c &lt; 6,0%

          -  Not anaemic

          -  Written informed consent

        Exclusion Criteria:

          -  Liver disease

          -  Nephropathy

          -  fasting plasma glucos &gt; 5,6mM

          -  Diabetes running in the family (parents or grandparents)

          -  Any medical treatment

          -  A former medical history of liver- or bile disease

          -  any surgical procedure conducted in the abdomen

          -  Body mass index &lt; 18,5 kg/m2 or &gt; 25 kg/m2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Copenhagen, Gentofte Hospital, Diabetic Research Division</name>
      <address>
        <city>Copenhagen, Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Krag Knop, MD, Ph.D.</last_name>
      <phone>(+45) 39778132</phone>
      <email>filipknop@dadlnet.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ulrich Rohde, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 31, 2012</lastchanged_date>
  <firstreceived_date>July 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>MD, Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Bile acids</keyword>
  <keyword>Gall bladder emptying</keyword>
  <keyword>Human</keyword>
  <keyword>Glucagon like peptide 1</keyword>
  <keyword>GLP-1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Colesevelam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
